Novel T-Cell Immunotherapies Market Size, Share & Trends Analysis Report By Type of T-cell Therapy (Activated T-cells, Virus Driven T-cells, Tregs, γδ T-cells, T-cell vaccines, and NK T-cells), By Disease Indication, Region, And Segment Forecasts, 2025-2034.

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Novel T-Cell Immunotherapies Market Snapshot Chapter 4. Global Novel T-Cell Immunotherapies Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Industry Analysis – Porter's Five Forces Analysis 4.7. Competitive Landscape & Market Share Analysis 4.8. Impact of Covid-19 Analysis 4.9. Clinical Trial/Pipeline Analysis Chapter 5. Market Segmentation 1: By T-cell Therapy Type Estimates & Trend Analysis 5.1. By T-cell Therapy Type & Market Share, 2024 & 2034 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By T-cell Therapy Type: 5.2.1. Activated T-cells 5.2.2. Virus Driven T-cells 5.2.3. Tregs 5.2.4. γδ T-cells 5.2.5. T-cell vaccines 5.2.6. NK T-cells Chapter 6. Market Segmentation 2: By Disease Indications Estimates & Trend Analysis 6.1. By Disease Indications & Market Share, 2020& 2030 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Disease Indications: 6.2.1. Lung cancer 6.2.2. Breast Cancer 6.2.3. Cytomegalovirus Infection 6.2.4. Glioblastoma 6.2.5. Hepatocellular Carcinoma 6.2.6. Acute Myeloid Leukemia 6.2.7. Ovarian Cancer 6.2.8. Type 1 Diabetes Mellitus 6.2.9. Sarcoma 6.2.10. HIV infections 6.2.11. Pancreatic Cancer 6.2.12. Other Disease Indications Chapter 7. Novel T-Cell Immunotherapies Market Segmentation 3: Regional Estimates & Trend Analysis 7.1. North America 7.1.1. North America Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts By T-cell Therapy Type, 2021-2034 7.1.2. North America Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034 7.1.3. North America Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by country, 2021-2034 7.2. Europe 7.2.1. Europe Novel T-Cell Immunotherapies Market revenue (US$ Million) By T-cell Therapy Type, 2021-2034 7.2.2. Europe Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034 7.2.3. Europe Novel T-Cell Immunotherapies Market revenue (US$ Million) by country, 2021-2034 7.3. Asia Pacific 7.3.1. Asia Pacific Novel T-Cell Immunotherapies Market revenue (US$ Million) By T-cell Therapy Type, 2021-2034 7.3.2. Asia Pacific Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034 7.3.3. Asia Pacific Novel T-Cell Immunotherapies Market revenue (US$ Million) by country, 2021-2034 7.4. Latin America 7.4.1. Latin America Novel T-Cell Immunotherapies Market revenue (US$ Million) By T-cell Therapy Type, (US$ Million) 7.4.2. Latin America Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034 7.4.3. Latin America Novel T-Cell Immunotherapies Market revenue (US$ Million) by country, (US$ Million) 2021-2034 7.5. Middle East & Africa 7.5.1. Middle East & Africa Novel T-Cell Immunotherapies Market revenue (US$ Million) By T-cell Therapy Type, (US$ Million) 7.5.2. Middle East & Africa Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034 7.5.3. Middle East & Africa Novel T-Cell Immunotherapies Market revenue (US$ Million) by country, (US$ Million) 2021-2034 Chapter 8. Competitive Landscape 8.1. Major Mergers and Acquisitions/Strategic Alliances 8.2. Company Profiles 8.2.1. Atara Biotherapeutics 8.2.2. AlloVir 8.2.3. Eureka Therapeutics 8.2.4. Eutilex 8.2.5. GammaDelta Therapeutics 8.2.6. NexImmune 8.2.7. OSE Immunotherapeutics 8.2.8. Tevogen Bio 8.2.9. WindMIL Therapeutics 8.2.10. Acepodia 8.2.11. Adaptate Therapeutics 8.2.12. Adicet 8.2.13. Cytomed Therapeutics 8.2.14. Gadeta 8.2.15. IN8bio 8.2.16. Kiromic Biopharma 8.2.17. Lava Therapeutics 8.2.18. Takeda Pharmaceuticals 8.2.19. TC Biopharm 8.2.20. ImCheck Therapeutics 8.2.21. Expression Therapeutics LLC 8.2.22. Triumvira Immunologics 8.2.23. PureTech Health 8.2.24. PhosphoGam 8.2.25. Caladrius Biosciences 8.2.26. Eli Lilly and Company 8.2.27. Miltenyi Biotec 8.2.28. Sangamo Therapeutics (TxCell) 8.2.29. Cellenkos Inc. 8.2.30. Pfizer Inc. 8.2.31. PolTREG S.A.. 8.2.32. Parvus Therapeutics 8.2.33. ILTOO Pharma 8.2.34. Philogen S.p.A. 8.2.35. TRACT Therapeutics, Inc. 8.2.36. REGiMMUNE Co, Ltd. 8.2.37. Roche 8.2.38. Celgene 8.2.39. AHEAD THERAPEUTICS S.L. 8.2.40. Other Prominent Players